Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Albany Molecular Research, Inc.
Alliance with U.S. NINDS to target neuromuscular disorders
August 10th, 2005
Albany Molecular Research, Inc., (AMRI) announced a 2-year research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) aimed at developing novel treatments for spinal muscular atrophy, a degenerative neuromuscular disease that causes muscle wasting and, in the most severe form, death. Under the terms of the agreement, AMRI will provide fee-for-service medicinal chemistry lead optimization on target compounds, including design and synthesis of analogs, as well as analysis of associated structure activity relationships. AMRI is providing these services to NINDS through a subcontract with Science Applications...
Source: Biotech Week (2005-08-10)
|
